Subjective effort perception and fatigue recovery after physical therapy session in tropical spastic paraparesis patients
DOI:
https://doi.org/10.33233/fb.v21i6.4022Keywords:
HTLV-I infections, tropical spastic paraparesis, fatigue, exerciseAbstract
Introdução: Vírus Linfotrópico de Células T Humana do Tipo-1 (HTLV-1) é um retrovírus que afeta os linfócitos T humano e desencadeia inflamação na medula, levando à paraparesia espástica tropical/mielopatia associada ao HTLV-1 (PET/MAH) com prejuízos funcionais. Tais disfunções podem influenciar nos efeitos da fisioterapia, gerando diferentes níveis de fadiga. Objetivo: Avaliar a percepção subjetiva de esforço e de recuperação de indivíduos com PET/MAH após sessão única de fisioterapia. Material e métodos: Incluíram-se 12 participantes sintomáticos para PET/MAH, de ambos os sexos, que foram submetidos uma vez ao protocolo fisioterapêutico. Os instrumentos avaliativos foram: Escala Modificada de Borg, Escala de Percepção Subjetiva de Recuperação (1º, 5º e 10º minuto após a sessão) e Escala de Incapacidade Neurológica do Instituto de Pesquisa Clínica Evandro Chagas – 2 (EIPEC). Resultados: Encontrou-se correlação moderada entre idade e taxa de percepção subjetiva de recuperação ao 1º (r = - 0,4923) e 5º (r = - 0,4913) minuto e entre índice do EIPEC-2 e taxa de percepção subjetiva de recuperação ao 1º (r = 0,3592) e 5º (r = - 0,3772) minuto. Conclusão: Indivíduos deste estudo com maior idade e grau de incapacidade neurológica têm menor percepção subjetiva de recuperação.
References
Sá KN, Macêdo MC, Andrade RP, Mendes SD, Martins JV, Baptista AF. Physiotherapy for human T-lymphotropic virus 1-associated myelopathy: review of the literature and future perspectives. J Multidiscip Healthc 2015;8:117-25. doi: 10.2147/jmdh.s71978
Takatani M, Crispim ME, Fraiji N, Stefani MMA, Kiesslich D. Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon. Rev Inst Med Trop 2017;59(5). doi: 10.1590/s1678-9946201759005
Thé G, Kazanji M. Na HTLV-I / II Vaccine: from animal models to clinical trials? J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(1):S191-8. doi: 10.1097/00042560-199600001-00029
Watanabe T. Current status of HTLV-1 infection. Int J Hematol 2011;94:430-4. doi: 10.1007/s12185-011-0934-4
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 Infection. Front Microbiol 2012;3:388. doi: 10.3389/fmicb.2012.00388
Catalan-Soares B, Carneiro-Proietti ABF, Proietti FA, Group IHR. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saúde Pública 2005;21(3):926-31. doi: 10.1590/s0102-311x200500030002
De Castro-Costa CM, Araújo AQC, Barreto MM, Takayanaqui OM, Sohler MP, Silva ELM et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses 2006;22(10):931-5. doi: 10.1089/aid.2006.22.931
Bangham CRM, Osame M. Cellular immune response to HTLV-1. Oncogene 2005;24:6035-46. doi: 10.1038/sj.onc.1208970
Gonçalves DU, Proietti FA, Barbosa-Stancioli EF, Martins ML, Ribas JG, Martins-Filho OA et al. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets 2008;7(2):98-107. doi: 10.2174/187152808785107642
Izumo S, Umehara F, Osame M. HTLV-I-associated myelopathy. Neuropathology 2000;20:S65-8. doi: 10.1046/j.1440-1789.2000.00320.x
Moxoto I, Boa-Sorte N, Nunes C, Mota A, Dumas A, Dourado I et al. Perfil sociodemográfico, epidemiológico e comportamental de mulheres infectadas pelo HTLV-1 em Salvador-Bahia, uma área endêmica para o HTLV. Rev Soc Bras Med Trop 2007;40(1):37-41. doi: 10.1590/s0037-86822007000100007
Gonçalves DU, Proietti FA, Ribas JGR, Araújo MG, Pinheiro SR, Guedes AC et al. Epidemiology, treatment, and prevention of human T-Cell Leukemia Virus Type 1-associated diseases. Clin Microbiol Rev 2010;23(3):577-89. doi: 10.1128/cmr.00063-09
Reiss DB, Freitas GS, Bastos RHC, Souza MA, Horiguchi CLF, Martins ML et al. Neurological outcomes analysis of HTLV-1 seropositive patients of the Interdisciplinary Research HTLV Group (GIPH) cohort, Brazil. Retrovirology 2014;11(1). doi: 10.1186/1742-4690-11-s1-p51
Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol 2012;3. doi: 10.3389/fmicb.2012.00389
Gotuzzo E, Cabrera J, Deza L, Verdonck K, Vandamme AM, Cairampoma R et al. Clinical characteristics of patients in Peru with human T Cell Lymphotropic Virus Type 1-associated tropical spastic paraparesis. Clin Infect Dis 2004;39(7):939-44. doi: 10.1086/423957
Kumor K, Pierzchala K. The problem of fatigue in neurological disorders. Wiad Lek 2006;59(9-10):685-91.
Twomey R, Saied JÁ, Kruger R, Culus-Reed SN, Temesi J, Millet JY. Neuromuscular fatigue during exercise: Methodological considerations, etiology and potential role in chronic fatigue. Neurophysiol Clin 2017;47(2):95-110. doi: 10.1016/j.neucli.2017.03.002
Penner IK, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol 2017;13(11):662-75. doi: 10.1038/nrneurol.2017.117
Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet 2004;363(9413):978-88. doi: 10.1016/s0140-6736(04)15794-2
Swain MG. Fatigue in chronic disease. Clin Sci 2000;99(1):1-8. doi: 10.1042/CS19990372
Menon N, Gupta A, Khanna M, Taly AB, Thennarasu K. Prevalence of depression, fatigue, and sleep disturbances in patients with myelopathy: Their relation with functional and neurological recovery. J Spinal Cord Med 2016;39(6):620-6. doi: 10.1179/2045772314y.0000000284
Halabchi F, Alizadeh Z, Sahraian MA, Abolhasani M. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol 2017;17(1):185. doi: 10.1186/s12883-017-0960-9
Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14(5):377-81. doi: 10.1249/00005768-198205000-00012
Laurent CM, Green JM, Bishop PA, Sjokvist J, Schumacker RE, Richardson MT et al. A practical approach to monitoring recovery: development of a perceived recovery status scale. J Strength Cond Res 2011;25(3):620-8. doi: 10.1519/JSC.0b013e3181c69ec6
Schmidt FR. Avaliação do desempenho da escala de incapacidade neurológica do Instituto de Pesquisa Clínica Evandro Chagas (EIPEC-2) para pacientes com mielopatia associada ao HTLV-1 [Dissertação]. Rio de Janeiro: Fiocruz; 2014.
Sairenji T, Yamanishi K, Tachibana Y, Bertoni G, Kurata T. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology 1995;38(5):269-73. doi: 10.1159/000150450
Kuppuswamy A. The fatigue conundrum. Brain 2017;140(8):2240-45. doi: 10.1093/brain/awx153
Pardini M1, Bonzano L, Roccatagliata L, Mancardi GL, Bove M. The fatigue-motor performance paradox in multiple sclerosis. Sci Rep 2013;3:2001. doi: 10.1038/srep02001
De Vries JM, Hagemans ML, Bussmann JB, van der Ploeg AT, van Doorn PA. Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease. Cell Mol Life Sci 2010;67(5):701-13. doi: 10.1007/s00018-009-0184-2
Umekita K, Okayama A. HTLV-1 Infection and rheumatic diseases. Front Microbiol 2020;11. doi: 10.3389/fmicb.2020.00152
Haziot ME, Gascon MR, Assone T, Fonseca LAM, Luiz OC, Smid J et al. Detection of clinical and neurological signs in apparently asymptomatic HTLV-1 infected carriers: Association with high proviral load. PLoS Negl Trop Dis 2019;13(5):e0006967. https://www.doi.org/10.1371/journal.pntd.0006967
Asquith B, Zhang Y, Mosley AJ, Lara CM, Wallace DL, Worth A et al. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. PNAS 2007;104(19):8035-40. doi: 10.1073/pnas.0608832104
Penko AL, Barkley JE, Koop MM, Alberts JL. Borg scale is valid for ratings of perceived exertion for individuals with Parkinson"™s disease. Int J Exerc Sci 2017;10(1):76-86. doi: 10.1249/01.mss.0000402937.98368.9a
Ponina IV, Novoselova IN, Valiullina SA, Machalov VA, Lukyanov VI. Personalized approach column and spinal cord injury, taking into account exercise tolerance. Vopr Kurortol Fizioter Lech Fiz Kult. 2019;96(4):25-35. doi: 10.17116/kurort20199604125
Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet 2004;363(9413):978-88. doi: 10.1016/s0140-6736(04)15794-2
Paolucci EM, Loukov D, Bowdish DME, Heisz, JJ. Exercise reduces depression and inflammation but intensity matters. Bio Psycho 2018;133:79-84. doi: 10.1016/j.biopsycho.2018.01.015
Published
Issue
Section
License
Copyright (c) 2021 Yana Mendonça Fonseca, Leonardo Brynne Ramos de Souza, Denise da Silva Pinto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are authorized for non-exclusive distribution of the version of the work published in this journal (eg, publishing in an institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
